Trial Profile
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ERY 974 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 10 Apr 2021 Results presented at the 112th Annual Meeting of the American Association for Cancer Research
- 21 Aug 2019 Status changed from active, no longer recruiting to completed.
- 05 Feb 2019 Status changed from suspended to active, no longer recruiting.